Milestone Pharmaceuticals Inc. (MIST) Stock

Milestone Pharmaceuticals Inc. (MIST) is a Healthcare stock trading at $1.30 (as of 2026-06-18), with a market capitalization of $176.79M and a trailing P/E of -2.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines. Its lead program is etripamil, in Phase III trials for paroxysmal supraventricular tachycardia and Phase II trials for atrial fibrillation with rapid ventricular rate, with a license and collaboration agreement with Ji Xing Pharmaceuticals for human prophylactic and therapeutic uses.

Valuation — source: SEC EDGAR (first-party)
Price	$1.30
Market Cap	$176.79M
P/E Ratio	-2.0
EV / EBITDA	-2.3
Price / Book	4.49
Price / Sales	51.25
DCF Value (model)	$-7.00
DCF Upside vs Price	-636.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$2.92M
Net Margin	-2159.5%
Return on Equity	-189.6%
Debt / Equity	1.61
Current Ratio	9.18
Revenue Growth (YoY)	-65.9%
EPS Growth (YoY)	-35.5%
FCF Growth (YoY)	15.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	-4.77 (distress)

Valuation vs Sector & Industry
Stock P/E	-2.0
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-109.7%
vs Industry	-111.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RTW INVESTMENTS, LP ($7.53M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Joseph G. Oliveto
Employees	33
Country	CA
IPO Date	2019-05-09

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.